Breast cancer
Description:
Available test Fluorescence in situ hybridisation of FFPE tissue sections for HER2 status
Clinical details:
The determination of HER2 status in patients with invasive ductal carcinoma is critical in patient management as it identifies patients who are likely to respond to Herceptin. FISH analysis is used as an adjunctive test in those patients where HER2 immunohistochemistry is borderline, or may also be used as a stand-alone first-line test.
Synonyms or keywords:
HER2, breast cancer, invasive ductal carcinoma, trastuzumab, herceptin
Department:
Location:
Sample type and Volume required:
FFPE tissue sections – 3-4µm sections on unstained Apes slides with accompanying HER2 immunohistochemistry slide for correlation
Turnaround time:
Current service turnaround times: 2-7 calendar days; National targets: Urgent samples - 95% reported within 14 days;
Contacts:
For clinical advice or interpretation of results, please contact the laboratory in the first instance.
Last updated: 07/08/2015
